-
Article
Open AccessEffects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
Erythropoiesis-stimulating agents (ESAs) increase red blood cell (RBC) production in bone marrow by activating the erythropoietin receptor (EpoR) on erythrocytic-progenitor cells. Erythropoiesis-stimulating ag...
-
Article
Open AccessMolecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform
Formalin-fixed, paraffin-embedded (FFPE) tumour tissue represents an immense but mainly untapped resource with respect to molecular profiling. The DASL (cDNA-mediated Annealing, Selection, extension, and Ligat...
-
Article
Open AccessOf mice and men: the evolution of animal welfare guidelines for cancer research
-
Article
Open AccessSide-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling
The expression of side-population (SP) cells and their relation to tumour-initiating cells (T-ICs) have been insufficiently studied in breast cancer (BC). We therefore evaluated primary cell cultures derived f...
-
Article
Open AccessProstate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
Recent studies have indicated that prostate cancer patients with the TMPRSS2–ERG gene fusion have a higher risk of recurrence. To identify markers associated with TMPRSS2–ERG fusion and prognostic of biochemical ...
-
Article
Open AccessPromises and caveats of in silico biomarker discovery
-
Article
Open AccessEGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality
The clinical experience recently reported with epidermal growth factor receptor (EGFR)-targeting drugs confirms the synergistic interactions observed between these compounds and conventional cytotoxic agents, ...
-
Article
Open AccessComparative analysis of xanafide cytotoxicity in breast cancer cell lines
Xanafide, a DNA-intercalating agent and topoisomerase II inhibitor, has previously demonstrated comparable cytotoxicity to the parent drug amonafide (NSC 308847). The current study was conducted to investigate...
-
Article
Open AccessVariation in RNA expression and genomic DNA content acquired during cell culture
Specific chromosomal abnormalities are increasingly recognised to be associated with particular tumour subtypes. These cytogenetic abnormalities define the sites of specific genes, the alteration of which is i...
-
Article
Open AccessOf (only) mice and men
-
Article
Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro
The mechanism of action of the novel heterocycle 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), structurally related to temozolomide, was studied in the human ovarian tumour cell line OVCAR-3. Our result...
-
Article
Abstracts of the 6th Canadian Neuro-Oncology Meeting May 18–21, 1994 Lake Louise, Alberta
-
Chapter
New Drug Trials
Although most malignant tumors are either largely refractory to current chemotherapy (e.g., melanoma) or responsive but incurable (e.g., breast and small cell lung cancer) some neoplasms such as choriocarcinom...
-
Article
Trimetrexate: a new antifol entering clinical trials
Trimetrexate, a 2,4-diaminoquinazoline derivative, is a new antifol recently introduced into clinical trials. It differs from methotrexate principally in its transport (not carrier-mediated), and its intracell...
-
Chapter
New Pyrimidine Nucleosides with Potent Antiviral Activity
Several years ago, the Organic Chemistry Laboratory of the Memorial Sloan-Kettering Cancer Center embarked upon a program for the synthesis of 2’-substituted arabinosyl-pyrimidine nucleosides as potential anti...
